Physician profile
Kaleo C Ede
NPI 1619058260
$11,923.85
in general payments reported to CMS, 2019-2025
19 companies · $6,616 in 2025
The $6,616 reported for 2025 was more than what 93% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,609 · 2020: $200 · 2021: $415 · 2022: $1,130 · 2023: $323 · 2024: $630 · 2025: $6,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,384 · Food and Beverage: $1,518 · Travel and Lodging: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,384.25 |
| Food and Beverage | $1,517.50 |
| Travel and Lodging | $667.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $6,439.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,214.34 | 2019-2023 | |
| Pfizer INC. | $898.69 | 2021-2024 | |
| Glaxosmithkline, LLC. | $579.64 | 2019-2025 | Benlysta |
| Abbvie INC. | $558.35 | 2019-2025 | Humira |
| Amgen INC. | $478.91 | 2019-2024 | Enbrel, Amjevita, Avsola |
| Aurinia Pharma U.S., INC. | $405.77 | 2021-2023 | Lupkynis |
| Sandoz INC. | $76.45 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $73.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.99 | 2024-2025 | Orencia |
| Genentech USA, INC. | $31.81 | 2019-2025 | Actemra |
| Ultragenyx Pharmaceutical INC. | $24.93 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.78 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.78 | 2023 | Cyltezo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $18.93 | 2019 | |
| Medexus Pharma, INC. | $13.27 | 2019 | |
| Bio Products Laboratory USA, INC. | $12.53 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleo Ede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.